TUCSON, Ariz. , Nov. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc.
(Nasdaq: AXDX ) today announced financial results for the third quarter ended September 30, 2024 . "We are excited by the momentum we're building across our innovation pipeline, underscored by the successful launch of the clinical trial for our WAVE TM system and the Gram-Negative assay. This quarter also marked a significant milestone with FDA clearance of our Accelerate Arc TM system, a testament to our commitment to breakthrough solutions in diagnostics," commented Jack Phillips , President and CEO of Accelerate Diagnostics, Inc.
"Alongside these advances, we've continued to make meaningful progress in our commercial strategy, all while exercising disciplined financial management, which we believe will help drive sustainable growth for our company," Mr. Phillips continued. Third Quarter 2024 Operating Highlights Began WAVE system and Gram-Negative assay clinical trial.
Received 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform. Continued to executed contract extensions with several strategic customers with approximately 75% of U.S.
Pheno® customers secured through the anticipated WAVE commercial launch, subject to regulatory approvals. In the United States , added five new contracted Pheno instruments during the quarter, ending the quarter with 352 clinically live revenue-generating instruments and another 77 contrac.